Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
9
×
clinical trials
9
×
life sciences
national blog main
fda
boston blog main
boston top stories
national top stories
new york blog main
new york top stories
san diego blog main
san francisco blog main
san francisco top stories
indiana blog main
san diego top stories
boston
europe top stories
indiana top stories
investing
national
novartis
raleigh-durham blog main
roche
seattle blog main
type 1 diabetes
venture capital
alnylam pharmaceuticals
boston university
boulder/denver blog main
boulder/denver top stories
cancer
deals
detroit blog main
detroit top stories
diabetes
drug development
eli lilly
europe blog main
medical devices
raleigh-durham top stories
What
patients
9
×
drug
fda
medicine
daily
diabetes
friday
market
million
new
startup
time
type
add
advantages
ago
alnylam
analytics
approval
approve
approved
atrophy
awaits
bar
beta
bid
bio
biofourmis
biologic
biological
bionics
blood
boehringer
bottleneck
brings
called
cancer
carbidopa
clinical
closed
Language
unset
Current search:
patients
×
biotech
×
" clinical trials "
×
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
6 years ago
Fixing the Clinical Trial Bottleneck by Making Patients a Priority